Show simple item record

dc.contributor.authorMajidi, J
dc.contributor.authorBarar, J
dc.contributor.authorBaradaran, B
dc.contributor.authorAbdolalizadeh, J
dc.contributor.authorOmidi, Y
dc.date.accessioned2018-08-26T09:37:34Z
dc.date.available2018-08-26T09:37:34Z
dc.date.issued2009
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58120
dc.description.abstractIn the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the normal tissue. To resolve such downsides, the cancer therapy modalities need to be advanced with more effective and tolerable treatments to specifically target the malignant cell with minimal adverse consequences. In fact, characteristically, the malignant diseases are self sufficiency in growth signals along with insensitivity to growth inhibition. They can also evade from apoptosis, have limitless replicative potential, induce angiogenesis and possess metastasis potential. Given that the most of these characteristics are often due to genetic defects, thus key to the development of targeted therapies is the ability to use such processes to phenotypically distinguish the tumor from its normal counterpart by its specific/selective markers. The therapeutic monoclonal antibodies (mAbs) are deemed to be a class of novel agents that can specifically target and disrupt molecular pathways underlying tumorigenesis. The mAbs are produced by a single clone of B-cells, and are monospecific and homogeneous. Since Kohler and Milstein heralded a new era in antibody research and clinical development by the discovery of hybridoma technology in 1975, more than 20 mAbs have been approved by the US Food and Drug Administration (FDA) for treatment of obdurate diseases, including different types of cancers. Mouse hybridomas were the first reliable source of monoclonal antibodies which were developed for several in vivo therapeutic applications. Accordingly, the recombinant antibodies have been reduced in size, rebuilt into multivalent molecules and fused with different moieties such as radionuclides, toxins and enzymes. The emergence of recombinant technologies, transgenic animals and phage display technology has revolutionized the selection, humanization and production of antibodies. This review focuses on implementation of the mAbs and nanobodies fragments for cancer therapy. © 2009 IOS Press and the authors. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofHuman Antibodies
dc.subjectacetylsalicylic acid
dc.subjectalemtuzumab
dc.subjectalpha fetoprotein
dc.subjectalx 0081
dc.subjectalx 0141
dc.subjectalx 0681
dc.subjectantibody conjugate
dc.subjectbasiliximab
dc.subjectbevacizumab
dc.subjectcalicheamicin
dc.subjectcarcinoembryonic antigen
dc.subjectcetuximab
dc.subjectchimeric antibody
dc.subjectclopidogrel
dc.subjectdoxorubicin
dc.subjectepithelial cell adhesion molecule
dc.subjectepratuzumab
dc.subjectetanercept
dc.subjectgemtuzumab ozogamicin
dc.subjectheparin
dc.subjectibritumomab tiuxetan
dc.subjectimmunoglobulin F(ab) fragment
dc.subjectimmunoglobulin G antibody
dc.subjectinfliximab
dc.subjectinterleukin 2
dc.subjectmonoclonal antibody
dc.subjectmonophenol monooxygenase
dc.subjectnanobodies
dc.subjectpanitumumab
dc.subjectrituximab
dc.subjecttositumomab i 131
dc.subjecttrastuzumab
dc.subjectunclassified drug
dc.subjectunindexed drug
dc.subjectacute granulocytic leukemia
dc.subjectadd on therapy
dc.subjectantibody affinity
dc.subjectantibody dependent lymphocytotoxicity
dc.subjectantibody engineering
dc.subjectantibody production
dc.subjectantibody response
dc.subjectantibody specificity
dc.subjectantibody structure
dc.subjectantigen binding
dc.subjectantigen expression
dc.subjectantigen recognition
dc.subjectapoptosis
dc.subjectB cell lymphoma
dc.subjectbacteriophage F1
dc.subjectbinding affinity
dc.subjectblood group Lewis system
dc.subjectbreast cancer
dc.subjectcancer immunotherapy
dc.subjectcancer inhibition
dc.subjectchimeraplasty
dc.subjectchronic lymphatic leukemia
dc.subjectclinical trial
dc.subjectcolorectal cancer
dc.subjectcomplement dependent cytotoxicity
dc.subjectcomplement system
dc.subjectCrohn disease
dc.subjectdisease model
dc.subjectdrug clearance
dc.subjectdrug cytotoxicity
dc.subjectdrug delivery system
dc.subjectdrug effect
dc.subjectdrug half life
dc.subjectdrug mechanism
dc.subjectdrug penetration
dc.subjectdrug receptor binding
dc.subjectdrug solubility
dc.subjectdrug targeting
dc.subjectdrug uptake
dc.subjectglaucoma
dc.subjecthead and neck cancer
dc.subjecthuman
dc.subjecthumoral immunity
dc.subjecthybridoma
dc.subjectimmunogenicity
dc.subjectisotope labeling
dc.subjectlung cancer
dc.subjectneoplasm
dc.subjectnonhodgkin lymphoma
dc.subjectnonhuman
dc.subjectpancreas cancer
dc.subjectparticle size
dc.subjectphage display
dc.subjectpriority journal
dc.subjectprostate cancer
dc.subjectprotein synthesis inhibition
dc.subjectprotein targeting
dc.subjectreview
dc.subjectrheumatoid arthritis
dc.subjectsolid tumor
dc.subjectstable angina pectoris
dc.subjecttreatment outcome
dc.subjecttumor model
dc.subjectAnimals
dc.subjectAntibodies
dc.subjectAntibodies, Monoclonal
dc.subjectAntigens, Neoplasm
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectMice
dc.subjectMutant Chimeric Proteins
dc.subjectNanoparticles
dc.subjectNeoplasms
dc.subjectProtein Engineering
dc.titleTarget therapy of cancer: Implementation of monoclonal antibodies and nanobodies
dc.typeArticle
dc.citation.volume18
dc.citation.issue3
dc.citation.spage81
dc.citation.epage100
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.3233/HAB-2009-0204


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record